If you qualify, our team will discuss the various GLP-1 agonists available, their potential benefits, side effects, and dosage forms
Consumers should discuss realistic expectations, risks, and alternatives with a licensed healthcare provider before starting any prescription weight-management medication
To improve transparency, Supplementary Table 7 summarizes molecule-specific pharmacokinetic and clinical considerations, including approximate half-life, label-informed discontinuation or washout recommendations before planned conception, representative human pregnancy-exposure evidence, reported adverse outcomes, and an interpretive certainty judgment
Drug development for non-alcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH), has been surprisingly challenging 1